Magazine article Drug Topics

Formulary Winners

Magazine article Drug Topics

Formulary Winners

Article excerpt

The most notable new product successes for 1998-in terms of hospital-formulary penetrationwere Plavix and Trovan, according to Hospital Research Associates (HRA).

Plavix (clopidogrel bisulfate), an antiplatelet agent co-marketed by Bristol-Myers Squibb and Sanofi, achieved an 86.5% formulary acceptance between March and December 1998. Trovan (trovafloxacin, Pfizer Inc.), a quinolone antibiotic, was accepted by 73.6% of the hospitals on HRA's panel in its oral form and by 66.4% in its injectable form.

The results were contained in HRA's Medical Trends in Hospital Formulary Committees, a monthly report covering all therapeutic classes. Findings are based on responses from more than 200 hospital pharmacy directors around the country.

Promising results

Recent data published in the publication Blood suggest that Amdray (valspodar), a multidrugresistance modulator being developed by Novartis Pharmaceutical Corp., may show promise in treating certain patients with acute myelogenous leukemia (AML) when used in combination with chemotherapy.

The data, which represent the results of a phase II multicenter study that was coordinated by researchers at Stanford University School of Medicine, involved 37 patients with AML in whom chemotherapy had not demonstrated efficacy or who had relapsed after chemotherapy. In this study, patients received a combination of mitoxantrone, etoposide, and cytarabine (MEC) and valspodar. Overall, complete or partial remission was achieved in 43% of patients (12 patients achieved complete remission; four achieved partial remission). …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.